Zhejiang Xinguang Pharmaceutical Co Ltd

Zhejiang Xinguang Pharmaceutical Co Ltd maintains a strong liquidity position, with a current ratio of 17.16, indicating significant short-term asset coverage over liabilities. The company is debt-free, as evidenced by a debt-to-equity ratio of 0.0, and has a total equity of 836.81 million CNY. However, the company reports negative net cash after subtracting total debt, signaling potential liquidity constraints despite its high current ratio. Profitability metrics show a return on equity (ROE) of 6.48% and a return on assets (ROA) of 6.1%, both below the typical thresholds for high-performing pharmaceutical firms. The company's net income of 54.21 million CNY on revenue of 265.36 million CNY yields a net margin of 20.43%, which is strong but must be compared to industry medians to assess relative performance. The company's revenue is concentrated in domestic markets, with Zhejiang Province as its primary market. No international revenue breakdown is available, and the company does not disclose segment-specific revenue figures, limiting visibility into geographic or product diversification. Outlook data is not provided in the input, but historical revenue growth is not explicitly stated. The company's capital expenditure of -3.48 million CNY suggests asset disposals or non-capitalized maintenance, which may reflect a conservative reinvestment strategy. The absence of a clear growth trajectory in the data limits the ability to project future performance. The company faces low dilution risk, with no difference between basic and diluted shares outstanding. However, the negative net cash position raises concerns about potential financing needs that could lead to future dilution. No recent filings or transcripts are provided to assess management commentary or strategic shifts. No recent events, such as earnings calls, regulatory filings, or strategic announcements, are included in the input data, limiting the ability to assess near-term operational or strategic developments.